Researchers urge policy action as injectable PrEP remains out of reach for many

In a new brief report, researchers caution against repeating past mistakes in HIV prevention, as high drug prices and insurance coverage issues have slowed uptake of long-acting, bimonthly injectable pre-exposure prophylaxis (PrEP) in recent…

Continue Reading

News Source: medicalxpress.com